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the cessation of capecitabine a￿  ects the recurrence rate, but 
dose reduction does not. ￿   is study presents a clinical guideline 
that chemotherapy using capecitabine should be continued 
even when the dose must be reduced because of complications. 
As indicated above, this study will become more meaningful if 
the dependences of the prognostic factors related to oncologic 
outcomes on dose reduction, dose cessation and complications 
can be determined by increasing the number of candidates and 
by lengthening follow-up period. Also, studies on the mani-
festation of the hydropyrimidine dehydrogenase gene, which 
is supposed to be related to complications of capecitabine [2] 
are necessary.
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Capecitabine has the same e￿  ect as intravenous 5-™  uorouacil/ 
leukovorin. At the same time, it ensures good compliance of 
patients because it is convenient to administer and is regarded 
as a safe chemotherapic agent because the rate of complica-
tions, such as diarrhea, stomatitis, nausea and neutropenia is 
low. However, an important d isadvantage is the higher inci-
dence of hand-foot syndrome. Hand-foot syndrome occurs in 
more than half the cases of monotherapy with capecitabine in 
patients with colorectal cancer, and severe hand-foot syn-
drome of grades 3 and 4 occurs in 20% of those cases. Hand-
foot syndrome occurs within the 4th cycle in more than 80-
90% of the cases, and the rate of cessation of chemotherapy is 
high once severe hand-foot syndrome occurs. ￿   erefore, it is 
important that the cessation be prevented by teaching the pa-
tients about hand-foot syndrome before the administration of 
capecitabine and by regulating the dose of capecitabine. ￿   e 
metabolites of capecitabine that are excreted from the kidney 
are presumed to cause hand-foot syndrome, so the incidence 
of hand-foot syndrome will decrease if the dose of capeciabine 
can be reduced based on an evaluation of renal function [1].
   ￿   at this study was published under the present conditions 
is signi˜  cant because studies on oncologic outcomes resulting 
from dose reduction and/or cessation of capecitabine due to 
complications are rare. In this study, the incidence of hand-foot 
syndrome was high, 65.9%, and the rate of dose reduction and/ 
or cessation was 39.5%. In addition, it has been reported that 
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